| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1022085363 |
| P356 | DOI | 10.1007/S10157-014-1044-4 |
| P698 | PubMed publication ID | 26293451 |
| P50 | author | Ayumu Nakashima | Q52815803 |
| P2093 | author name string | Kensuke Sasaki | |
| Shigehiro Doi | |||
| Takao Masaki | |||
| Yukio Yokoyama | |||
| Toru Kawai | |||
| Kenta Fujiwara | |||
| Asuka Aoki | |||
| Kotaro Soji | |||
| Yasufumi Kyuden | |||
| P2860 | cites work | Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin | Q24298747 |
| Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms | Q24299673 | ||
| The ANG-(1-7)/ACE2/mas axis in the regulation of nephron function | Q24633556 | ||
| Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes | Q28188162 | ||
| The vacuolar (H+)-ATPases--nature's most versatile proton pumps | Q28218190 | ||
| Oral renin inhibitors | Q28269879 | ||
| Cardiorenal end points in a trial of aliskiren for type 2 diabetes | Q28278569 | ||
| Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | Q29615215 | ||
| Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data | Q30656350 | ||
| Telmisartan, ramipril, or both in patients at high risk for vascular events | Q33156143 | ||
| Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial | Q34372881 | ||
| Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition | Q34602504 | ||
| Current knowledge of (pro)renin receptor as an accessory protein of vacuolar H+-ATPase | Q37965494 | ||
| Revised equations for estimated GFR from serum creatinine in Japan | Q39513402 | ||
| Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. | Q40509707 | ||
| Aliskiren inhibits intracellular angiotensin II levels without affecting (pro)renin receptor signals in human podocytes | Q42465866 | ||
| Proteinuria and the risk of developing end-stage renal disease | Q44358762 | ||
| Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design | Q46162422 | ||
| Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
| Aliskiren combined with losartan in type 2 diabetes and nephropathy | Q46558669 | ||
| Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats | Q46587391 | ||
| Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. | Q53562530 | ||
| Urinary protein as measured with a pyrogallol red-molybdate complex, manually and in a Hitachi 726 automated analyzer | Q69566790 | ||
| P433 | issue | 4 | |
| P921 | main subject | chronic renal insufficiency | Q736715 |
| P304 | page(s) | 631-638 | |
| P577 | publication date | 2014-10-22 | |
| P1433 | published in | Clinical and experimental nephrology | Q26842022 |
| P1476 | title | Efficacy of add-on therapy of aliskiren to an angiotensin II receptor blocker on renal outcomes in advanced-stage chronic kidney disease: a prospective, randomized, open-label study | |
| P478 | volume | 19 |
Search more.